Venugopal Marar

, Led global pharmacovigilance and drug development activities across all phases of clinical development and post-marketing lifecycle management in compliance with FDA, EMA, MHRA, PMDA, and ICH regulations.

• Directed safety surveillance, signal detection, benefit–risk assessments, and risk management strategies for investigational and marketed products, supporting informed development and regulatory decisions.
• Provided strategic safety leadership for IND, NDA, BLA, and global regulatory submissions, including IBs, DSURs, PBRERs/PSURs, CCDS, RMPs, REMS, protocols, and Clinical Study Reports.
• Collaborated with Clinical Development, Regulatory Affairs, Medical Affairs, Biostatistics, and HEOR teams to integrate safety insights into clinical trial design, dose optimization, and product development strategies.
• Represented Drug Safety in Health Authority interactions, Safety Management Teams, Data Monitoring Committees, and cross-functional governance forums to support global product development programs.
• Evaluated cumulative safety data from clinical trials, spontaneous reports, literature, and real-world evidence to identify emerging safety signals and support global labeling updates and risk minimization activities.
• Applied deep knowledge of global pharmacovigilance regulations, GCP/GVP requirements, and ICH guidelines to ensure regulatory compliance, inspection readiness, and proactive patient safety oversight across global programs.

• Delivered strategic medical safety leadership across global programs, ensuring robust pharmacovigilance frameworks.
• Oversaw development and implementation of standard operating procedures for safety processes.
• SMT chair for Signals both clinical trials and PM
• Guided cross-functional alignment on safety strategies, integrating priorities into clinical development.
• Led comprehensive safety management activities for investigational and marketed products, including risk mitigation plans.
• Provided medical leadership for risk management and aggregate safety reporting, including development of REMS and RMP strategies and oversight of PBRER and PADER preparation, ensuring robust benefit–risk evaluation and compliance with global pharmacovigilance regulations.
• Conducted ongoing medical review of safety data and continuous benefit-risk evaluations across global trials.
• Supported key documents in IND /NDA submissions (CTD, briefing book etc)
• Provided medical input into protocol development, protocol amendments, and study-related documents.
• Partnered with HEOR and RWE teams to integrate real-world safety data into benefit–risk assessments, supporting regulatory submissions and payer decision-making.
• Contributed pharmacovigilance expertise to health economic models (cost-effectiveness, cost-utility) by providing safety event rates, discontinuation data, and adverse event burden impacting QALYs.
• Supported design and execution of real-world evidence (RWE) studies by defining safety endpoints, identifying confounders, and analyzing data from sources such as FDA Adverse Event Reporting System and EudraVigilance.
• Identified emerging risks and recommended proactive mitigations aligned with regulatory expectations.
• Directed signal detection activities, including medical evaluation of case reports and trend analysis.
• Collaborated with clinical development and regulatory affairs to support benefit-risk analyses. Making.
• Led and maintained pharmacovigilance systems in compliance with EU Good Pharmacovigilance Practices (GVP) and global PV regulations (EMA, ICH, FDA).
• Dat bases: Argus Medidata Rave, EVDAS, Tableau, Spotfire, Empirica
• Provided strategic oversight of GVP-compliant PV operations across clinical development and post-marketing lifecycle.
• Ensured end-to-end alignment of PV activities with GVP Modules I, V, VI, VII, and IX.
• Led end-to-end US REMS strategy aligned with FDA requirements, global RMPs, and evolving patient safety priorities.
• Oversee the preparation of key documents, Reference Safety Information, safety sections of Investigator Brochures, protocols, informed consent forms, clinical study reports, regulatory responses, and other key documents.
• Directed design, approval, and implementation of REMS programs, including restricted distribution, prescriber/pharmacy certification, and patient enrollment systems
• Provided medical support for audits and inspections as needed
• Provided strategic input into RMPs and REMS assessments; drove continuous optimization of risk minimization measures
• Managed REMS vendors (call centers, specialty pharmacies, certification platforms) ensuring compliance, high-quality training, and data integrity
• Oversaw execution of REMS commitments and cross-functional risk integration activities.
• Presented safety data on the product during key meetings (e.g., with Health Authorities, Data Safety Monitoring Boards and Investigators).
• Led US safety labeling (USPI, Medication Guides, REMS content) and ensured timely submission of aggregate reports (PADERs, PBRERs)
• Served as primary liaison for US safety inquiries, escalations, and Health Authority interactions
• Ensured audit and inspection readiness; managed findings and CAPAs through to closure
• Interpreted evolving regulatory requirements to strengthen REMS and safety strategy
• Represented organization in FDA interactions, REMS negotiations, and industry forums
• Ensured audit and inspection readiness; managed findings and CAPAs through to closure.

• Led the design and execution of global clinical development programs aligned with medical, scientific, regulatory, and commercial objectives across early-through late-phase development.
• Medical Monitor on Phase I–IV clinical trials
• Provided strategic medical leadership across the product lifecycle (Phase 1–3) for internally developed and partnered assets.
• Oversaw end-to-end clinical trial execution, partnering with Clinical Operations to drive enrollment, timeline adherence, and on-time delivery of key milestones.
• Ensured proactive safety oversight in collaboration with Pharmacovigilance, including SAE review, medical monitoring, and compliance with global safety reporting requirements.
• Directed the development and scientific integrity of core clinical documents, including protocols, Investigator's Brochures, CSRs, regulatory dossiers, and health authority response packages.

• Provide strategic medical safety leadership across early development (FIH, dose escalation, PoC), clinical development, and post-marketing programs, ensuring compliance with ICH, GCP, FDA, EMA, and global pharmacovigilance regulations.
• Senior Physician for global medical safety assessment for development assets on Argus.
• Serve as product safety physician and medical monitor, overseeing clinical trial safety, SAE/ICSR review, signal evaluation, and spontaneous reporting for investigational and marketed products.
• Lead and maintain signal detection strategies and plans, performing continuous analysis of clinical and post-marketing safety data to identify emerging risks and trends, with emphasis on early-phase programs.
• Collaborate with Early Development and Clinical teams to embed safety considerations into protocol design, first-in-human risk assessments, dose escalation strategies, and stopping rules.
• Author, review, and maintain Company Core Safety Information (CCSI/CCDS) and safety sections of INDs, NDAs, MAAs, CSRs, and Investigator's Brochures, ensuring accuracy and regulatory alignment.
• Lead preparation and review of aggregate safety deliverables, including PSURs/PBRERs, DSURs, ad hoc safety analyses, AOSEs, and safety summaries supporting global submissions.
• Develop, implement, and oversee Risk Management Plans (RMPs) and REMS, including identification of important risks, missing information, and risk minimization measures.
• Represent Clinical Safety & Pharmacovigilance at Labeling Committees, Safety Review Committees, and executive governance forums, providing clear medical risk–benefit assessments.
• Serve as primary safety liaison with Regulatory Affairs, supporting health authority interactions and responses to safety-related questions from FDA, EMA, and global regulators.
• Review and approve clinical trial medical coding (MedDRA), protocols, CRFs, informed consent language, patient narratives, and safety sections of regulatory documents.
• Mentor and provide scientific oversight to safety physicians, scientists, and pharmacovigilance associates, delivering training on signal detection, risk management, and regulatory safety requirements.
• Partner cross-functionally with Clinical Development, Biostatistics, Medical Affairs, CROs, and external partners to ensure aligned, inspection-ready safety strategy execution.

• Oversaw the conduct of global clinical studies in full compliance with company standards and applicable regulatory and industry requirements, including ICH-GCP.
• Led the scientific review and approval of Investigator-Sponsored Trial (IST) concepts and protocols in accordance with internal SOPs and governance processes.
• Partnered closely with U.S. Drug Safety/Pharmacovigilance to manage clinical trial adverse events and post-marketing safety data, including evaluation and communication of emerging safety signals.
• Built and maintained strong professional relationships with Key Opinion Leaders (KOLs), investigators, and professional societies to represent the organization and strengthen its scientific reputation within the therapeutic area.
• Maintained current knowledge of scientific and clinical advances through continuous literature review, participation in scientific congresses, professional associations, and medical forums.
• Identified evidence gaps across the development and post-marketing continuum and informed the execution of integrated evidence-generation strategies.
• Provided medical leadership and strategic direction for external scientific engagements and communications with key stakeholders, institutions, and strategic partners.
• Integrated safety data (AE rates, severity, discontinuations) into HEOR cost-effectiveness and budget impact models, influencing ICER outcomes and payer value narratives while partnering with HEOR and Market Access teams
• Led evaluation of emerging safety signals and translated clinical risk into economic impact (costs, utilities, healthcare resource utilization), enabling refinement of HEOR models
• Provided critical safety inputs (Grade ≥3 AEs, hospitalization rates, treatment discontinuation) to inform QALY and cost assumptions, ensuring alignment with utility decrements and real-world treatment patterns
• Drove safety labeling updates (USPI/CCDS) with direct implications on adherence, persistence, and HEOR model assumptions; supported regulatory interactions with agencies such as FDA and EMA
• Collaborated on real-world evidence studies integrating safety and effectiveness outcomes, strengthening external validity of payer-facing evidence and linking adverse events to healthcare utilization and cost burden
• Informed REMS and RMP strategies that reduced adverse event burden and improved projected QALYs, supporting favorable reimbursement positioning
• Shaped cross-functional safety–value strategy aligning pharmacovigilance outputs with HEOR evidence generation and anticipated the impact of safety profiles on payer acceptance, reimbursement outcomes, and market uptake
• Contributed to improved ICER positioning and supported successful HTA and value dossier submissions.

• Conducted thorough review of scientific literature, validated safety signals and lead safety signal assessments, and developed and core safety information (core data sheet, core risks in informed consent forms, etc.).
• Prepared/reviewed core and regional risk management plans including additional risk minimization measures.
• Reviewed EudraVigilance cases and steered medical assessments of SUSAR, AOSE, adverse events of special interests.
• Inputted safety protocols, statistical analysis plans, and clinical study reports.
• Performed medical review of Individual Case Safety Report (ICSR) mainly from clinical trials, as well as from literature, post marketing studies and post marketing spontaneous reports to determine the event seriousness, expectedness, company causality, ensure complete and timely review aligning with internal and external reporting timelines.
• Conducted reconciliation of cases between Eudravigilance data base and Argus.
• Supported product registration and renewals activities.

• Conducted case reviews on Aris G (post marketing and clinical development), delivered oversight of benefit/risk safety profile of allocated products through product lifecycle, and led safety profiles.
• Reviewed clinical trial data and post marketing data.
• Medical Monitor on Phase I–IV clinical trials
• Spearheaded development and medical affairs product teams in identifying and handling product safety concerns.
• Played key role in Benefit-Risk reports, RMPs/REMS etc.) and supported product registration and renewals activities.
• Contracted with Baxalta – Cambridge, MA

• Led all safety and risk management of Oncology products, generated aggregate data reports to maintain data integrity, supported clinical study protocols, and led communication of recommendations to labeling group.
• Facilitated Internal Safety Monitoring Committees (SMC) meetings, provided input to SMC Charters, and represented SMT in Company Safety Committee (CSC) meetings.
• Documented safety sections of clinical documents, including new and approval of safety portion of protocols.
• Chaired Safety Management Team (SMT) meetings for signal detection and reviews of SMT materials.
• Provided necessary input into development and review of safety reports (DSURs, IND reports, PADERs, PSUR, /PBRER, Benefit-Risk reports, RMPs/REMS etc.) and to support product registration and renewals activities.
• Involved in escalation of non-compliance to the EEA QPPV and Head of GPV.
• Contracted with Merck Pharmaceuticals – Rahway, NJ

• Served in a contract capacity with Pioneer Data Systems to support consumer health products and cardiology drugs.
• Assessed post marketing safety data and generated aggregate reports (PSUR, DSUR, CTPR).
• Completed CAPA documents and led team on mitigation strategies.
• Adhered to best clinical practices and regulations.
• Performed data reconciliation to ensure capture of all adverse events.
• Worked on safety data on different data bases (Argus AND SCEPTRE).
• Vendor: Johnson & Johnson – Morris Plains, NJ

• Processed SUSAR cases from clinical trial and ICSR from post-marketed, literature, with an accuracy and consistency at various stages of the system workflow.
• Generated queries using ARGUS interface for clarification, resolving and forwarding to next workflow and communicated to out-side sources to retrieve the required information on the case report.
• Contribution in safety sections of documents IND and NDA.
• Consistently used ARGUS features such as action items, contact log and worklist for communication and for the follow-up requests.
• Medical review of Protocols and Informed consents.
• Contract / Remote

• Received, documented and processed SUSAR from clinical trials and post-marketing in accordance with company Standard Operating Procedures (SOPs).
• Performed case Prioritization/Triaging based on seriousness of adverse events in accordance with SOP guidelines.
• Processed cases with an accuracy and consistency at various stages of the system workflow.
• Prepared clinical narrative summaries for AE reports independently from clinical studies and post-marketing reports.
• Contract / Remote/onsite

• Monitored product performance during dermatological studies.
• Conducted safety risk analyses on Argus version 4.2, authored clinical study protocols, evaluated causality assessments, and managed individual case safety report activities.
• Worked closely with Regulatory, NDA Submission, Labeling, Laboratory, and sales teams.
• Functioned as Product Safety Management Team Lead for business and research units.
• (Cosmetics/Skin care) – Clark, New Jersey

• Managed clinical trials for Johnson & Johnson and Parexel.
• Oversaw informed consent process, site master file maintenance, and validation of causality assessment of adverse and serious adverse effects.
• Obtained, processed, and shipped serum and blood specimens.
• Participated in project and investigator meetings.
• New York

• Mifepristone/olanzapine trial.